Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lemaitre Vascular (LMAT) Other Non Operating Income (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Other Non Operating Income for 16 consecutive years, with -$581000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 144.12% to -$581000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$638000.0 through Dec 2025, down 410.4% year-over-year, with the annual reading at -$638000.0 for FY2025, 410.4% down from the prior year.
  • Other Non Operating Income for Q4 2025 was -$581000.0 at Lemaitre Vascular, down from -$306000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $384000.0 in Q4 2022, with the low at -$581000.0 in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$75900.0, with a median of -$56000.0 recorded in 2021.
  • The sharpest move saw Other Non Operating Income soared 3590.91% in 2022, then plummeted 962.5% in 2023.
  • Over 5 years, Other Non Operating Income stood at -$11000.0 in 2021, then skyrocketed by 3590.91% to $384000.0 in 2022, then plummeted by 70.05% to $115000.0 in 2023, then plummeted by 306.96% to -$238000.0 in 2024, then tumbled by 144.12% to -$581000.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$581000.0, -$306000.0, and $247000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.